Sphingolipids and Atherosclerosis: The Dual Role of Ceramide and Sphingosine-1-Phosphate

Sphingolipids are bioactive molecules that play either pro- and anti-atherogenic roles in the formation and maturation of atherosclerotic plaques. Among SLs, ceramide and sphingosine-1-phosphate showed antithetic properties in regulating various molecular mechanisms and have emerged as novel potential targets for regulating the development of atherosclerosis. In particular, maintaining the balance of the so-called ceramide/S1P rheostat is important to prevent the occurrence of endothelial dysfunction, which is the trigger for the entire atherosclerotic process and is strongly associated with increased oxidative stress. In addition, these two sphingolipids, together with many other sphingolipid mediators, are directly involved in the progression of atherogenesis and the formation of atherosclerotic plaques by promoting the oxidation of low-density lipoproteins (LDL) and influencing the vascular smooth muscle cell phenotype. The modulation of ceramide and S1P levels may therefore allow the development of new antioxidant therapies that can prevent or at least impair the onset of atherogenesis, which would ultimately improve the quality of life of patients with coronary artery disease and significantly reduce their mortality.

[1]  Li-ling Guo,et al.  Novel insight on the role of Macrophages in atherosclerosis: Focus on polarization, apoptosis and efferocytosis. , 2022, International immunopharmacology.

[2]  K. Alka,et al.  Regulation of serine palmitoyl-transferase and Rac1–Nox2 signaling in diabetic retinopathy , 2022, Scientific Reports.

[3]  W. Kuebler,et al.  Sphingolipids in Atherosclerosis: Chimeras in Structure and Function , 2022, International journal of molecular sciences.

[4]  Shiming Liu,et al.  The Acid Sphingomyelinase Inhibitor Amitriptyline Ameliorates TNF-α-Induced Endothelial Dysfunction , 2022, Cardiovascular Drugs and Therapy.

[5]  A. Cudnoch-Jędrzejewska,et al.  Sphingolipid metabolism and signaling in cardiovascular diseases , 2022, Frontiers in Cardiovascular Medicine.

[6]  G. Nickenig,et al.  Ceramide Metabolism in Cardiovascular Disease: A Network With High Therapeutic Potential. , 2022, Arteriosclerosis, thrombosis, and vascular biology.

[7]  B. Levkau,et al.  Sphingosine-1-Phosphate (S1P) Lyase Inhibition Aggravates Atherosclerosis and Induces Plaque Rupture in ApoE−/− Mice , 2022, International journal of molecular sciences.

[8]  D. Meyerholz,et al.  Cordyceps inhibits ceramide biosynthesis and improves insulin resistance and hepatic steatosis , 2022, Scientific Reports.

[9]  Duolu Li,et al.  Lipidomics Analysis Reveals Protective Effect of Myriocin on Cerebral Ischemia/Reperfusion Model Rats , 2022 .

[10]  Goon-Tae Kim,et al.  De Novo Sphingolipid Biosynthesis in Atherosclerosis. , 2022, Advances in Experimental Medicine and Biology.

[11]  P. Dörmann,et al.  Activation of neutral sphingomyelinase 2 through hyperglycemia contributes to endothelial apoptosis via vesicle-bound intercellular transfer of ceramides , 2021, Cellular and Molecular Life Sciences.

[12]  I. König,et al.  Ceramide accumulation induces mitophagy and impairs β-oxidation in PINK1 deficiency , 2021, Proceedings of the National Academy of Sciences.

[13]  K. Sandhoff,et al.  Acid Sphingomyelinase, a Lysosomal and Secretory Phospholipase C, Is Key for Cellular Phospholipid Catabolism , 2021, International journal of molecular sciences.

[14]  E. Fisher,et al.  Fate and State of Vascular Smooth Muscle Cells in Atherosclerosis. , 2021, Circulation.

[15]  I. D. Zelnik,et al.  The Complex Tail of Circulating Sphingolipids in Atherosclerosis and Cardiovascular Disease , 2021, Journal of lipid and atherosclerosis.

[16]  F. Lang,et al.  Acid sphingomyelinase promotes SGK1-dependent vascular calcification. , 2021, Clinical science.

[17]  C. Pappone,et al.  The antithetic role of ceramide and sphingosine‐1‐phosphate in cardiac dysfunction , 2021, Journal of cellular physiology.

[18]  F. Foufelle,et al.  Dihydroceramides: Their emerging physiological roles and functions in cancer and metabolic diseases. , 2020, American journal of physiology. Endocrinology and metabolism.

[19]  P. Jeppesen,et al.  Endothelial dysfunction in small arteries and early signs of atherosclerosis in ApoE knockout rats , 2020, Scientific Reports.

[20]  V. Saini,et al.  Mechanistic Insights into the Oxidized Low-Density Lipoprotein-Induced Atherosclerosis , 2020, Oxidative medicine and cellular longevity.

[21]  Y. Zhang,et al.  Associations between plasma ceramides and mortality in patients with coronary artery disease. , 2020, Atherosclerosis.

[22]  D. Benvenuto,et al.  Endothelial Sphingolipid De Novo Synthesis Controls Blood Pressure by Regulating Signal Transduction and NO via Ceramide , 2020, Hypertension.

[23]  J. Rutter,et al.  Reign in the membrane: How common lipids govern mitochondrial function. , 2020, Current opinion in cell biology.

[24]  Zhiyuan Shen,et al.  Myriocin and D-PDMP ameliorate atherosclerosis in ApoE-/-mice via reducing lipid uptake and vascular inflammation. , 2020, Clinical science.

[25]  R. Paroni,et al.  Inhibition of Sphingolipid Synthesis as a Phenotype-Modifying Therapy in Cystic Fibrosis. , 2020, Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology.

[26]  R. Laaksonen,et al.  Associations between specific plasma ceramides and severity of coronary-artery stenosis assessed by coronary angiography. , 2020, Diabetes & Metabolism.

[27]  Hai-Jian Sun,et al.  Role of Endothelial Dysfunction in Cardiovascular Diseases: The Link Between Inflammation and Hydrogen Sulfide , 2020, Frontiers in Pharmacology.

[28]  R. Proia,et al.  Sphingosine kinase-2 prevents macrophage cholesterol accumulation and atherosclerosis by stimulating autophagic lipid degradation , 2019, Scientific Reports.

[29]  S. Summers,et al.  Metabolic Messengers: ceramides , 2019, Nature Metabolism.

[30]  C. Pappone,et al.  Sphingolipid Synthesis Inhibition by Myriocin Administration Enhances Lipid Consumption and Ameliorates Lipid Response to Myocardial Ischemia Reperfusion Injury , 2019, Front. Physiol..

[31]  D. Radzioch,et al.  Biochemistry of very-long-chain and long-chain ceramides in cystic fibrosis and other diseases: The importance of side chain. , 2019, Progress in lipid research.

[32]  Qian Li,et al.  ApoM-S1P Modulates Ox-LDL-Induced Inflammation Through the PI3K/Akt Signaling Pathway in HUVECs , 2018, Inflammation.

[33]  S. Swendeman,et al.  Sphingosine 1‐Phosphate Receptor 1 Signaling Maintains Endothelial Cell Barrier Function and Protects Against Immune Complex–Induced Vascular Injury , 2018, Arthritis & rheumatology.

[34]  W. Lukiw,et al.  The Cross-Talk Between Sphingolipids and Insulin-Like Growth Factor Signaling: Significance for Aging and Neurodegeneration , 2018, Molecular Neurobiology.

[35]  R. Proia,et al.  Elevating Endogenous Sphingosine-1-Phosphate (S1P) Levels Improves Endothelial Function and Ameliorates Atherosclerosis in Low Density Lipoprotein Receptor-Deficient (LDL-R−/−) Mice , 2018, Thrombosis and Haemostasis.

[36]  M. Perola,et al.  Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths , 2018, European heart journal.

[37]  F. Goñi,et al.  The Physical Properties of Ceramides in Membranes. , 2018, Annual review of biophysics.

[38]  E. Schuchman,et al.  Ceramide and Ischemia/Reperfusion Injury , 2018, Journal of lipids.

[39]  M. Kurano,et al.  Sphingosine 1-Phosphate and Atherosclerosis , 2018, Journal of atherosclerosis and thrombosis.

[40]  K. Rottner,et al.  Cortactin: Cell Functions of A Multifaceted Actin-Binding Protein. , 2017, Trends in cell biology.

[41]  R. de Caterina,et al.  Endothelial permeability, LDL deposition, and cardiovascular risk factors—a review , 2018, Cardiovascular research.

[42]  M. Nicholls Plasma ceramides and cardiac risk , 2017 .

[43]  F. Paris,et al.  Plasma membrane reorganization links acid sphingomyelinase/ceramide to p38 MAPK pathways in endothelial cells apoptosis. , 2017, Cellular signalling.

[44]  J. Chun,et al.  Identification of Sphingosine 1-Phosphate Receptor Subtype 1 (S1P1) as a Pathogenic Factor in Transient Focal Cerebral Ischemia , 2017, Molecular Neurobiology.

[45]  T. Hla,et al.  Vascular and Immunobiology of the Circulatory Sphingosine 1-Phosphate Gradient. , 2017, Annual review of physiology.

[46]  Nicolas Foin,et al.  Biomechanical stress in coronary atherosclerosis: emerging insights from computational modelling , 2016, European heart journal.

[47]  J. Nofer,et al.  High density lipoprotein (HDL)-associated sphingosine 1-phosphate (S1P) inhibits macrophage apoptosis by stimulating STAT3 activity and survivin expression. , 2015, Atherosclerosis.

[48]  A. Engin What Is Lipotoxicity? , 2017, Advances in experimental medicine and biology.

[49]  W. Pan,et al.  Acid Sphingomyelinase Mediates Oxidized-LDL Induced Apoptosis in Macrophage via Endoplasmic Reticulum Stress , 2016, Journal of atherosclerosis and thrombosis.

[50]  A. Pandolfi,et al.  Physiology and pathophysiology of oxLDL uptake by vascular wall cells in atherosclerosis. , 2016, Vascular pharmacology.

[51]  A. Orekhov,et al.  Macrophages and Their Role in Atherosclerosis: Pathophysiology and Transcriptome Analysis , 2016, BioMed research international.

[52]  A. Xu,et al.  Thirty Years of Saying NO: Sources, Fate, Actions, and Misfortunes of the Endothelium-Derived Vasodilator Mediator. , 2016, Circulation research.

[53]  J. Borén,et al.  Sphingolipids Contribute to Human Atherosclerotic Plaque Inflammation. , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[54]  Kim Ekroos,et al.  Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol , 2016, European heart journal.

[55]  M. Bennett,et al.  Vascular Smooth Muscle Cells in Atherosclerosis. , 2016, Circulation research.

[56]  P. Serruys,et al.  Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: Results of the ATHEROREMO-IVUS study. , 2015, Atherosclerosis.

[57]  S. Mochida,et al.  Inhibitor-1 and -2 of PP2A have preference between PP2A complexes. , 2015, Biochemical and biophysical research communications.

[58]  Deborah Jones,et al.  Ceramide-Initiated Protein Phosphatase 2A Activation Contributes to Arterial Dysfunction In Vivo , 2015, Diabetes.

[59]  S. Spiegel,et al.  Revisiting the sphingolipid rheostat: Evolving concepts in cancer therapy. , 2015, Experimental cell research.

[60]  Oliver Soehnlein,et al.  Chemokines control mobilization, recruitment, and fate of monocytes in atherosclerosis. , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[61]  Ira Tabas,et al.  Recent insights into the cellular biology of atherosclerosis , 2015, The Journal of cell biology.

[62]  Y. Hannun,et al.  Critical determinants of mitochondria-associated neutral sphingomyelinase (MA-nSMase) for mitochondrial localization. , 2015, Biochimica et biophysica acta.

[63]  Wei Chen,et al.  Role of sphingosine-1-phosphate receptor 1 and sphingosine-1-phosphate receptor 2 in hyperglycemia-induced endothelial cell dysfunction. , 2015, International journal of molecular medicine.

[64]  Tamara J. Blätte,et al.  Phenotypic Regulation of the Sphingosine 1-Phosphate Receptor Miles Apart by G Protein-Coupled Receptor Kinase 2 , 2015, Biochemistry.

[65]  S. Batra,et al.  NADPH oxidases: an overview from structure to innate immunity-associated pathologies , 2014, Cellular and Molecular Immunology.

[66]  H. Lei,et al.  Akt/eNOS signaling pathway mediates inhibition of endothelial progenitor cells by palmitate-induced ceramide. , 2015, American journal of physiology. Heart and circulatory physiology.

[67]  Julie K. Freed,et al.  Ceramide Changes the Mediator of Flow-Induced Vasodilation From Nitric Oxide to Hydrogen Peroxide in the Human Microcirculation , 2014, Circulation research.

[68]  T. Hla,et al.  An update on the biology of sphingosine 1-phosphate receptors , 2014, Journal of Lipid Research.

[69]  R. Erbel,et al.  HDL-Bound Sphingosine 1-Phosphate (S1P) Predicts the Severity of Coronary Artery Atherosclerosis , 2014, Cellular Physiology and Biochemistry.

[70]  Ann Saada,et al.  Ceramide and the mitochondrial respiratory chain. , 2014, Biochimie.

[71]  G. Shulman,et al.  Ceramide-activated phosphatase mediates fatty acid-induced endothelial VEGF resistance and impaired angiogenesis. , 2014, The American journal of pathology.

[72]  Si Jin,et al.  Endogenous Ceramide Contributes to the Transcytosis of oxLDL across Endothelial Cells and Promotes Its Subendothelial Retention in Vascular Wall , 2014, Oxidative medicine and cellular longevity.

[73]  Santiago Lamas,et al.  Hydrogen peroxide signaling in vascular endothelial cells , 2014, Redox biology.

[74]  B. Sellergren,et al.  Lipidomic "deep profiling": an enhanced workflow to reveal new molecular species of signaling lipids. , 2014, Analytical chemistry.

[75]  T. Byzova,et al.  Oxidative stress in angiogenesis and vascular disease. , 2014, Blood.

[76]  T. Ueland,et al.  Matrix Metalloproteinase 7 Is Associated with Symptomatic Lesions and Adverse Events in Patients with Carotid Atherosclerosis , 2014, PloS one.

[77]  W. März,et al.  Molecular Lipids Identify Cardiovascular Risk and Are Efficiently Lowered by Simvastatin and PCSK9 Deficiency , 2013, The Journal of clinical endocrinology and metabolism.

[78]  Lihe Lu,et al.  Ceramide Mediates Ox-LDL-Induced Human Vascular Smooth Muscle Cell Calcification via p38 Mitogen-Activated Protein Kinase Signaling , 2013, PloS one.

[79]  K. Moore,et al.  Macrophages in atherosclerosis: a dynamic balance , 2013, Nature Reviews Immunology.

[80]  Y. Hannun,et al.  A signaling cascade mediated by ceramide, src and PDGFRβ coordinates the activation of the redox-sensitive neutral sphingomyelinase-2 and sphingosine kinase-1. , 2013, Biochimica et biophysica acta.

[81]  M. Kurano,et al.  Liver involvement in sphingosine 1-phosphate dynamism revealed by adenoviral hepatic overexpression of apolipoprotein M. , 2013, Atherosclerosis.

[82]  C. Weber,et al.  KRP-203, Sphingosine 1-Phosphate Receptor Type 1 Agonist, Ameliorates Atherosclerosis in LDL-R−/− Mice , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[83]  P. Hopkins,et al.  Molecular biology of atherosclerosis. , 2013, Physiological reviews.

[84]  J. Martín-Ventura,et al.  HDL and endothelial protection , 2013, British journal of pharmacology.

[85]  C. Christoffersen,et al.  The Apolipoprotein M–Sphingosine-1-Phosphate Axis: Biological Relevance in Lipoprotein Metabolism, Lipid Disorders and Atherosclerosis , 2013, International journal of molecular sciences.

[86]  R. Proia,et al.  Shaping the landscape: metabolic regulation of S1P gradients. , 2013, Biochimica et biophysica acta.

[87]  S. Saddoughi,et al.  Diverse functions of ceramide in cancer cell death and proliferation. , 2013, Advances in cancer research.

[88]  Yang Zhang,et al.  Cross talk between ceramide and redox signaling: implications for endothelial dysfunction and renal disease. , 2013, Handbook of experimental pharmacology.

[89]  G. Sakuta,et al.  Sphingosine-1-phosphate: distribution, metabolism and role in the regulation of cellular functions. , 2013, Ukrains'kyi biokhimichnyi zhurnal.

[90]  S. Barman,et al.  From form to function: the role of Nox4 in the cardiovascular system , 2012, Front. Physio..

[91]  H. Griffiths,et al.  Palmitate promotes monocyte atherogenicity via de novo ceramide synthesis. , 2012, Free radical biology & medicine.

[92]  Liping Wei,et al.  FTY720 Protects Cardiac Microvessels of Diabetes: A Critical Role of S1P1/3 in Diabetic Heart Disease , 2012, PloS one.

[93]  M. Riekkola,et al.  Conformational changes of apoB-100 in SMase-modified LDL mediate formation of large aggregates at acidic pH[S] , 2012, Journal of Lipid Research.

[94]  N. Ferreirós,et al.  Long chain ceramides and very long chain ceramides have opposite effects on human breast and colon cancer cell growth. , 2012, The international journal of biochemistry & cell biology.

[95]  E. Abel,et al.  Ceramide Mediates Vascular Dysfunction in Diet-Induced Obesity by PP2A-Mediated Dephosphorylation of the eNOS-Akt Complex , 2012, Diabetes.

[96]  I. Petrache,et al.  Mechanisms of lung endothelial barrier disruption induced by cigarette smoke: role of oxidative stress and ceramides. , 2011, American journal of physiology. Lung cellular and molecular physiology.

[97]  L. Moreno,et al.  Neutral sphingomyelinase, NADPH oxidase and reactive oxygen species. Role in acute hypoxic pulmonary vasoconstriction , 2011, Journal of cellular physiology.

[98]  Zhou Junlin,et al.  Inhibition of ceramide synthesis reverses endothelial dysfunction and atherosclerosis in streptozotocin-induced diabetic rats. , 2011, Diabetes research and clinical practice.

[99]  B. Dahlbäck,et al.  Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M , 2011, Proceedings of the National Academy of Sciences.

[100]  Jonathan D. Smith,et al.  Sphingosine-1-Phosphate Receptor-2 Function in Myeloid Cells Regulates Vascular Inflammation and Atherosclerosis , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[101]  I. Goldberg,et al.  Sphingolipids and cardiovascular diseases: lipoprotein metabolism, atherosclerosis and cardiomyopathy. , 2011, Advances in experimental medicine and biology.

[102]  G. Caimi,et al.  [Oxidative stress and endothelial dysfunction]. , 2011, Minerva medica.

[103]  E. Kremmer,et al.  Shaping of terminal megakaryocyte differentiation and proplatelet development by sphingosine‐1‐phosphate receptor S1P4 , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[104]  Sarah Spiegel,et al.  International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid Receptor Nomenclature , 2010, Pharmacological Reviews.

[105]  A. Bielawska,et al.  Blood sphingolipidomics in healthy humans: impact of sample collection methodology , 2010, Journal of Lipid Research.

[106]  Xiao-yong Lei,et al.  Caveolae and caveolin-1 mediate endocytosis and transcytosis of oxidized low density lipoprotein in endothelial cells , 2010, Acta Pharmacologica Sinica.

[107]  R. Erbel,et al.  Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease , 2010, Basic Research in Cardiology.

[108]  A. Futerman,et al.  Mammalian ceramide synthases , 2010, IUBMB life.

[109]  Yang Zhang,et al.  Ceramide in Redox Signaling and Cardiovascular Diseases , 2010, Cellular Physiology and Biochemistry.

[110]  N. Mochizuki,et al.  Sphingosine 1-Phosphate ( S 1 P ) Regulates Vascular Contraction via S 1 P 3 Receptor : Investigation Based on a New S 1 P 3 Receptor Antagonist , 2010 .

[111]  F. Pecker,et al.  Sphingomyelinases: their regulation and roles in cardiovascular pathophysiology. , 2009, Cardiovascular research.

[112]  P. Hordijk,et al.  Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases , 2009, Journal of leukocyte biology.

[113]  B. Levkau,et al.  Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. , 2008, Cardiovascular research.

[114]  A. Verin,et al.  Reprint of "The role of cytoskeleton in the regulation of vascular endothelial barrier function" [Microvascular Research 76 (2008) 202-207]. , 2009, Microvascular research.

[115]  V. Taviani,et al.  The mechanical triggers of plaque rupture: shear stress vs pressure gradient. , 2009, The British journal of radiology.

[116]  K. Williams,et al.  Acid Sphingomyelinase Promotes Lipoprotein Retention Within Early Atheromata and Accelerates Lesion Progression , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[117]  S. Hammad,et al.  High Density Lipoprotein-associated Sphingosine 1-Phosphate Promotes Endothelial Barrier Function* , 2008, Journal of Biological Chemistry.

[118]  S. Wrenn,et al.  Effect of sphingomyelinase-mediated generation of ceramide on aggregation of low-density lipoprotein. , 2008, Langmuir : the ACS journal of surfaces and colloids.

[119]  T. Michel,et al.  S1P and eNOS regulation. , 2008, Biochimica et biophysica acta.

[120]  T. Hla,et al.  The vascular S1P gradient-cellular sources and biological significance. , 2008, Biochimica et biophysica acta.

[121]  S. Lorkowski,et al.  HDL-Associated Lysosphingolipids Inhibit NAD(P)H Oxidase–Dependent Monocyte Chemoattractant Protein-1 Production , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[122]  C. García-Rodríguez,et al.  Selective attenuation of Toll-like receptor 2 signalling may explain the atheroprotective effect of sphingosine 1-phosphate. , 2008, Cardiovascular research.

[123]  T. Littlewood,et al.  Chronic Apoptosis of Vascular Smooth Muscle Cells Accelerates Atherosclerosis and Promotes Calcification and Medial Degeneration , 2008, Circulation research.

[124]  L. Badimón,et al.  Prostacyclin induction by high-density lipoprotein (HDL) in vascular smooth muscle cells depends on sphingosine 1-phosphate receptors: Effect of simvastatin , 2008, Thrombosis and Haemostasis.

[125]  Y. Hannun,et al.  The sphingolipid salvage pathway in ceramide metabolism and signaling. , 2008, Cellular signalling.

[126]  Chad A. Corcoran,et al.  Neutral Sphingomyelinase-3 Is a DNA Damage and Nongenotoxic Stress-Regulated Gene That Is Deregulated in Human Malignancies , 2008, Molecular Cancer Research.

[127]  H. Bonkovsky,et al.  Vascular Endothelium As a Contributor of Plasma Sphingosine 1-Phosphate , 2008, Circulation research.

[128]  Takuya Shimizu,et al.  Sphingosine 1-Phosphate Receptor 2 Negatively Regulates Neointimal Formation in Mouse Arteries , 2007, Circulation research.

[129]  J. Borén,et al.  Ira Tabas , Kevin Jon Williams and Jan Borén and Therapeutic Implications Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis : Update , 2007 .

[130]  S. Dudek,et al.  Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor. , 2007, Cellular Signalling.

[131]  B. Levkau,et al.  HDL and its sphingosine-1-phosphate content in cardioprotection , 2007, Heart Failure Reviews.

[132]  E. Gulbins,et al.  Acid sphingomyelinase and its redox amplification in formation of lipid raft redox signaling platforms in endothelial cells. , 2007, Antioxidants & redox signaling.

[133]  J. Cyster,et al.  Promotion of Lymphocyte Egress into Blood and Lymph by Distinct Sources of Sphingosine-1-Phosphate , 2007, Science.

[134]  R. Proia,et al.  Deafness and Stria Vascularis Defects in S1P2 Receptor-null Mice* , 2007, Journal of Biological Chemistry.

[135]  Y. Hannun,et al.  Redox regulation of neutral sphingomyelinase-1 activity in HEK293 cells through a GSH-dependent mechanism. , 2007, Archives of biochemistry and biophysics.

[136]  G. Assmann,et al.  FTY720, a Synthetic Sphingosine 1 Phosphate Analogue, Inhibits Development of Atherosclerosis in Low-Density Lipoprotein Receptor–Deficient Mice , 2007, Circulation.

[137]  C. Weber,et al.  Platelets as Immune Cells: Bridging Inflammation and Cardiovascular Disease , 2007, Circulation research.

[138]  H. Katus,et al.  Sphingosine-1-Phosphate Analogue FTY 720 Causes Lymphocyte Redistribution and Hypercholesterolemia in ApoE-Deficient Mice , 2007 .

[139]  B. Levkau,et al.  The Sphingosine-1-Phosphate Analogue FTY 720 Reduces Atherosclerosis in Apolipoprotein E – Deficient Mice , 2007 .

[140]  K. Krause,et al.  The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. , 2007, Physiological reviews.

[141]  M. Bennett,et al.  The Emerging Role of Vascular Smooth Muscle Cell Apoptosis in Atherosclerosis and Plaque Stability , 2007, American Journal of Nephrology.

[142]  Chulhee Choi,et al.  Role of NADPH oxidase 4 in lipopolysaccharide-induced proinflammatory responses by human aortic endothelial cells. , 2006, Cardiovascular research.

[143]  F. Visioli,et al.  Age‐related changes in endothelial nitric oxide synthase phosphorylation and nitric oxide dependent vasodilation: evidence for a novel mechanism involving sphingomyelinase and ceramide‐activated phosphatase 2A , 2006, Aging cell.

[144]  E. Gulbins,et al.  TRAIL activates acid sphingomyelinase via a redox mechanism and releases ceramide to trigger apoptosis , 2006, Oncogene.

[145]  S. Ben-Dor,et al.  When Do Lasses (Longevity Assurance Genes) Become CerS (Ceramide Synthases)? , 2006, Journal of Biological Chemistry.

[146]  R. Proia,et al.  Extracellular export of sphingosine kinase-1a contributes to the vascular S1P gradient. , 2006, The Biochemical journal.

[147]  B. Kriem,et al.  Soluble oligomers of amyloid-β peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway , 2006, Neurobiology of Disease.

[148]  Michal Levy,et al.  nSMase2 activation and trafficking are modulated by oxidative stress to induce apoptosis. , 2006, Biochemical and biophysical research communications.

[149]  U. Förstermann,et al.  Endothelial Nitric Oxide Synthase in Vascular Disease: From Marvel to Menace , 2006, Circulation.

[150]  E. Gulbins,et al.  Lipid Raft Clustering and Redox Signaling Platform Formation in Coronary Arterial Endothelial Cells , 2006, Hypertension.

[151]  P. Xia High-Density Lipoproteins and Their Constituent, Sphingosine-1-Phosphate, Directly Protect the Heart Against Ischemia/Reperfusion Injury In Vivo via the S1P 3 Lysophospholipid Receptor , 2006 .

[152]  T. Michel,et al.  Rac 1 Modulates Sphingosine 1-Phosphate-mediated Activation of Phosphoinositide 3-Kinase / Akt Signaling Pathways in Vascular Endothelial Cells * , 2006 .

[153]  S. Dudek,et al.  Regulation of sphingosine 1‐phosphate‐induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and α‐actinin , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[154]  G. Assmann,et al.  Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids. , 2005, Trends in cardiovascular medicine.

[155]  H. Cai Hydrogen peroxide regulation of endothelial function: origins, mechanisms, and consequences. , 2005, Cardiovascular research.

[156]  W. Stahl,et al.  Nutritional, dietary and postprandial oxidative stress. , 2005, The Journal of nutrition.

[157]  M. Hojjati,et al.  Effect of Myriocin on Plasma Sphingolipid Metabolism and Atherosclerosis in apoE-deficient Mice* , 2005, Journal of Biological Chemistry.

[158]  M. Hersberger,et al.  Current understanding of the metabolism and biological actions of HDL , 2005, Current opinion in clinical nutrition and metabolic care.

[159]  W. Erl,et al.  Stable Knock-Down of the Sphingosine 1-Phosphate Receptor S1P1 Influences Multiple Functions of Human Endothelial Cells , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[160]  Koichi Sato,et al.  High-density lipoprotein inhibits migration of vascular smooth muscle cells through its sphingosine 1-phosphate component. , 2005, Atherosclerosis.

[161]  M. Rekhter,et al.  Inhibition of Sphingomyelin Synthesis Reduces Atherogenesis in Apolipoprotein E–Knockout Mice , 2004, Circulation.

[162]  A. Hermetter,et al.  Role of ceramide in activation of stress-associated MAP kinases by minimally modified LDL in vascular smooth muscle cells. , 2004, Biochimica et biophysica acta.

[163]  J. Keaney,et al.  Role of oxidative modifications in atherosclerosis. , 2004, Physiological reviews.

[164]  S. Itohara,et al.  Role for Matrix Metalloproteinase-2 in Oxidized Low-Density Lipoprotein–Induced Activation of the Sphingomyelin/Ceramide Pathway and Smooth Muscle Cell Proliferation , 2004, Circulation.

[165]  Sarah Spiegel,et al.  Generation and metabolism of bioactive sphingosine‐1‐phosphate , 2004, Journal of cellular biochemistry.

[166]  S. Dudek,et al.  Interaction of cortactin and Arp2/3 complex is required for sphingosine-1-phosphate-induced endothelial cell remodeling. , 2004, Experimental cell research.

[167]  E. Goetzl,et al.  Sphingosine 1‐phosphate and its type 1 G protein‐coupled receptor: trophic support and functional regulation of T Lymphocytes , 2004, Journal of leukocyte biology.

[168]  Jacek Bielawski,et al.  Role for Mammalian Neutral Sphingomyelinase 2 in Confluence-induced Growth Arrest of MCF7 Cells* , 2004, Journal of Biological Chemistry.

[169]  J. Chun,et al.  Lysophospholipid receptors: signaling and biology. , 2004, Annual review of biochemistry.

[170]  M. Zou,et al.  Peroxynitrite and vascular endothelial dysfunction in diabetes mellitus. , 2004, Endothelium : journal of endothelial cell research.

[171]  G. Assmann,et al.  HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. , 2004, The Journal of clinical investigation.

[172]  K. Claffey,et al.  Phosphorylation and Action of the Immunomodulator FTY720 Inhibits Vascular Endothelial Cell Growth Factor-induced Vascular Permeability* , 2003, Journal of Biological Chemistry.

[173]  J. Garcia,et al.  Role of sphingosine-1 phosphate in the enhancement of endothelial barrier integrity by platelet-released products. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[174]  K. Hanada,et al.  Serine palmitoyltransferase, a key enzyme of sphingolipid metabolism. , 2003, Biochimica et biophysica acta.

[175]  T. Michel,et al.  Sphingosine 1-phosphate and control of vascular tone. , 2003, American journal of physiology. Heart and circulatory physiology.

[176]  E. Clementi,et al.  Activation of endothelial nitric-oxide synthase by tumor necrosis factor-alpha: a novel pathway involving sequential activation of neutral sphingomyelinase, phosphatidylinositol-3' kinase, and Akt. , 2003, Molecular pharmacology.

[177]  A. Alonso,et al.  Sphingomyelinases: enzymology and membrane activity , 2002, FEBS letters.

[178]  U. Förstermann,et al.  Dual Effect of Ceramide on Human Endothelial Cells: Induction of Oxidative Stress and Transcriptional Upregulation of Endothelial Nitric Oxide Synthase , 2002, Circulation.

[179]  E. Kostenis,et al.  Comparative analysis of human and rat S1P(5) (edg8): differential expression profiles and sensitivities to antagonists. , 2002, Biochemical pharmacology.

[180]  Alfred H. Merrill,et al.  De Novo Sphingolipid Biosynthesis: A Necessary, but Dangerous, Pathway* , 2002, The Journal of Biological Chemistry.

[181]  D. Manning,et al.  Pathways of transduction engaged by sphingosine 1-phosphate through G protein-coupled receptors. , 2002, Biochimica et biophysica acta.

[182]  W. R. Taylor,et al.  Superoxide Production and Expression of Nox Family Proteins in Human Atherosclerosis , 2002, Circulation.

[183]  Y. Hannun,et al.  Selective hydrolysis of a mitochondrial pool of sphingomyelin induces apoptosis , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[184]  T. Hla,et al.  Role of the Sphingosine 1-Phosphate Receptor EDG-1 in Vascular Smooth Muscle Cell Proliferation and Migration , 2001, Circulation research.

[185]  A. Verin,et al.  Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. , 2001, The Journal of clinical investigation.

[186]  E Vicaut,et al.  Rapid reactive oxygen species production by mitochondria in endothelial cells exposed to tumor necrosis factor-alpha is mediated by ceramide. , 2001, American journal of respiratory cell and molecular biology.

[187]  D. Granger,et al.  Adhesion molecules and their role in vascular disease. , 2001, American journal of hypertension.

[188]  Pin-Lan Li,et al.  Ceramide Reduces Endothelium-Dependent Vasodilation by Increasing Superoxide Production in Small Bovine Coronary Arteries , 2001, Circulation research.

[189]  E. Clementi,et al.  Activation of the Endothelial Nitric-oxide Synthase by Tumor Necrosis Factor-α , 2001, The Journal of Biological Chemistry.

[190]  R. Kinscherf,et al.  Ceramide induces aSMase expression: implications for oxLDL-induced apoptosis , 2001 .

[191]  D. Brindley,et al.  Platelet-released phospholipids link haemostasis and angiogenesis. , 2001, Cardiovascular research.

[192]  Obeid,et al.  The Sphingomyelin Cycle and the Second Messenger Function of Ceramide " , 2001 .

[193]  M. Ui,et al.  Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. , 2000, The Biochemical journal.

[194]  M. Colombini,et al.  The Lipids C2- and C16-Ceramide Form Large Stable Channels , 2000, The Journal of Biological Chemistry.

[195]  M. Kester,et al.  Ceramide Directly Activates Protein Kinase C ζ to Regulate a Stress-activated Protein Kinase Signaling Complex* , 2000, The Journal of Biological Chemistry.

[196]  A. Azzi,et al.  Vitamin E reduces the uptake of oxidized LDL by inhibiting CD36 scavenger receptor expression in cultured aortic smooth muscle cells. , 2000, Circulation.

[197]  S. Milstien,et al.  Sphingosine‐1‐phosphate: signaling inside and out , 2000, FEBS letters.

[198]  R. E. Pitas,et al.  Class A Scavenger Receptor Up-regulation in Smooth Muscle Cells by Oxidized Low Density Lipoprotein* , 2000, The Journal of Biological Chemistry.

[199]  Z. Fuks,et al.  Ceramide mediates radiation‐induced death of endothelium , 2000, Critical care medicine.

[200]  J. Keaney,et al.  Redox control of vascular nitric oxide bioavailability. , 2000, Antioxidants & redox signaling.

[201]  John G. Collard,et al.  Rac Downregulates Rho Activity: Reciprocal Balance between Both Gtpases Determines Cellular Morphology and Migratory Behavior , 1999 .

[202]  K. Claffey,et al.  Vascular Endothelial Cell Adherens Junction Assembly and Morphogenesis Induced by Sphingosine-1-Phosphate , 1999, Cell.

[203]  A. Barr,et al.  Differential Coupling of the Sphingosine 1-Phosphate Receptors Edg-1, Edg-3, and H218/Edg-5 to the Gi, Gq, and G12 Families of Heterotrimeric G Proteins* , 1999, The Journal of Biological Chemistry.

[204]  J. Boyle Vascular smooth muscle cell apoptosis in atherosclerosis , 1999, International journal of experimental pathology.

[205]  S. Kimura,et al.  The novel sphingosine 1-phosphate receptor AGR16 is coupled via pertussis toxin-sensitive and -insensitive G-proteins to multiple signalling pathways. , 1999, The Biochemical journal.

[206]  J. Gamble,et al.  Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[207]  D. Choi,et al.  Involvement of de Novo Ceramide Biosynthesis in Tumor Necrosis Factor-α/Cycloheximide-induced Cerebral Endothelial Cell Death* , 1998, The Journal of Biological Chemistry.

[208]  C. H. Liu,et al.  Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. , 1998, Science.

[209]  K. Williams,et al.  Human Vascular Endothelial Cells Are a Rich and Regulatable Source of Secretory Sphingomyelinase , 1998, The Journal of Biological Chemistry.

[210]  W. Edwards,et al.  Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology. , 1998, Journal of the American College of Cardiology.

[211]  R. Kolesnick,et al.  Kinase Suppressor of Ras Is Ceramide-Activated Protein Kinase , 1997, Cell.

[212]  J. Skepper,et al.  FOAM CELL APOPTOSIS AND THE DEVELOPMENT OF THE LIPID CORE OF HUMAN ATHEROSCLEROSIS , 1996, The Journal of pathology.

[213]  S. Spiegel,et al.  Sphingolipid metabolism and cell growth regulation , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[214]  K. Williams,et al.  Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. , 1996, The Journal of clinical investigation.

[215]  A. Nègre-Salvayre,et al.  The Sphingomyelin-Ceramide Signaling Pathway Is Involved in Oxidized Low Density Lipoprotein-induced Cell Proliferation* , 1996, The Journal of Biological Chemistry.

[216]  W D Wagner,et al.  A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[217]  R. Cohen,et al.  Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle , 1994, Nature.

[218]  Y. Hannun,et al.  Programmed cell death induced by ceramide. , 1993, Science.

[219]  I. Tabas,et al.  Sphingomyelinase enhances low density lipoprotein uptake and ability to induce cholesteryl ester accumulation in macrophages. , 1991, The Journal of biological chemistry.

[220]  A. J. Valente,et al.  Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. , 1991, The Journal of clinical investigation.

[221]  P. Vanhoutte,et al.  Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. , 1986, The American journal of physiology.

[222]  R. Frye,et al.  A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. , 1975, Circulation.

[223]  E. Smith,et al.  Intimal and medial lipids in human aortas. , 1960, Lancet.